Flavoxate Treatment of Micturition Disorders Accompanying Benign Prostatic Hypertrophy: A Double-Blind Placebo-Controlled Multicenter Investigation

Dahm, TL; Ostri, P; Kristensen, Jørgen Kvist; Walter, Steen; Frimodt-Møller, C; Rasmussen, R.B.; Nøhr, M.; Alexander, Niels

doi:10.1159/000282787

Cited by 30 publications

(25 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors suggested that flavoxate does not appear to be beneficial in the medical management of detrusor instability. Finally, Dahm et al investigated the effect of flavoxate on symptomatic benign prostatic hypertrophy in a double-blind, parallel-group, placebo-controlled multicenter study [34]. Of 70 patients included, 37 received 400 mg flavoxate three times daily for 12 weeks, and 33 received placebo.…”

Section: Efficacy and Head-to-head Comparative Studies Of Flavoxatementioning

confidence: 99%

Flavoxate in urogynecology: an old drug revisited

2014

View full text Add to dashboard Cite

We conclude that the minimal side effects and high tolerability of flavoxate make it worthy of consideration for the treatment of several clinical urogynecological conditions. It deserves more clinical studies to assess its efficacy as no randomized controlled trials have been performed with flavoxate during the last decade. More studies and novel drug formulations may reveal or improve its efficacy in daily practice.

show abstract

Section: Efficacy and Head-to-head Comparative Studies Of Flavoxatementioning

confidence: 99%

Flavoxate in urogynecology: an old drug revisited

2014

View full text Add to dashboard Cite

show abstract

“…[22,23,24]. Briggs et al [22] studied the effect of flavoxate on only 6 elderly patients with uninhibited detrusor contractions associated with urinary incontinence and consequently the outcomes of their study have to be interpreted with caution.…”

Section: Flavoxate Hydrochloridementioning

confidence: 99%

“…Briggs et al [22] studied the effect of flavoxate on only 6 elderly patients with uninhibited detrusor contractions associated with urinary incontinence and consequently the outcomes of their study have to be interpreted with caution. However, Chapple et al [23] reported in 1990 on a double-blind, placebo-controlled, crossover trial of flavoxate in idiopathic detrusor instability, while Dahm et al [24] provided a randomized, double-blind, parallel-group, placebo-controlled and multicenter investigation with adequate statistical power on the efficacy of flavoxate 400 mg t.i.d. for the treatment of OAB.…”

Section: Flavoxate Hydrochloridementioning

confidence: 99%

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

Asimakopoulos

Cerruto²,

Popolo³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Objectives: To provide an overview on the efficacy, tolerability, safety and health-related quality of life (HRQoL) of drugs with a mixed action used in the treatment of overactive bladder (OAB). Evidence Acquisition: MEDLINE database and abstract books of the major conferences were searched for relevant publications from 1966 to 2011 and using the key words ‘overactive bladder’, ‘detrusor overactivity’, ‘oxybutynin’, ‘propiverine’, and ‘flavoxate’. Two independent reviewers considered publications for inclusion and extracted relevant data, without performing a meta-analysis. Evidence Synthesis: Old and conflicting data do not support the use of flavoxate, while both propiverine and oxybutynin were found to be more effective than placebo in the treatment of OAB. Propiverine was at least as effective as oxybutynin but with a better tolerability profile even in the pediatric setting. Overall, no serious adverse event for any product was statistically significant compared to placebo. Improvements were seen in HRQoL with treatment by the oxybutynin transdermal delivery system and propiverine extended release. Conclusions: While there is no evidence to suggest the use of flavoxate in the treatment of OAB, both oxybutynin and propiverine appear efficacious and safe. Propiverine shows a better tolerability profile than oxybutynin. Both drugs improve HRQoL of patients affected by OAB. Profiles of each drug and dosage differ and should be considered in making treatment choices.

show abstract

“…Dahm et al [ 13 ] investigated 70 men with BPH, Qmax < 10 mL/sec, and nocturia over a 12-week period. Patients were given fl avoxate and compared with patients given placebo.…”

Section: Rcts With a Clinical Diagnosis Of Bph And Lutsmentioning

confidence: 99%

Anticholinergics in men: Does the evidence support combination therapy?

Sellaturay¹,

Blake-James

2008

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is common in men older than age 50, and the symptoms occurring from bladder outlet obstruction (BOO) commonly overlap with lower urinary tract symptoms (LUTS) experienced in overactive bladder (OAB). Anticholinergics are often withheld from men with BOO. This article reviews seven randomized controlled trials (RCTs) and a meta-analysis study examining anticholinergic use in men with LUTS associated with OAB and BPH. There is growing evidence that anticholinergics are a suitable, safe treatment in men with persistent LUTS associated with BOO, refractory to α -blockers. Only four of 750 men treated with anticholinergics in the seven RCTs reviewed had acute urinary retention. Further well-designed, placebo-controlled RCTs are required to assess the effi cacy and long-term safety outcomes of combination therapy. However, it appears feasible to effectively use adjunctive anticholinergic therapy in men with LUTS/BPH and no signifi cant increase in postvoid residual volume.

show abstract

Flavoxate Treatment of Micturition Disorders Accompanying Benign Prostatic Hypertrophy: A Double-Blind Placebo-Controlled Multicenter Investigation

Cited by 30 publications

References 6 publications

Flavoxate in urogynecology: an old drug revisited

Flavoxate in urogynecology: an old drug revisited

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

Anticholinergics in men: Does the evidence support combination therapy?

Contact Info

Product

Resources

About